ZMapp reverses Ebola virus disease

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp
Xiangguo Qiu, et al.
Nature. 29 August 2014
http://www.nature.com/nature/journal/vnfv/ncurrent/full/nature13777.html

Without an approved vaccine or treatment, Ebola outbreak management has been limited to palliative care and barrier methods to prevent transmission.
These approaches, however, have yet to end the 2014 outbreak of Ebola after its prolonged presence in West Africa.
Here we show that a combination of monoclonal antibodies (ZMapp), optimized from two previous antibody cocktails, is able to rescue 100% of rhesus macaques when treatment is initiated up to 5 days post-challenge.
High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many animals before ZMapp intervention. Advanced disease, as indicated by elevated liver enzymes, mucosal haemorrhages and generalized petechia could be reversed, leading to full recovery. ELISA and neutralizing antibody assays indicate that ZMapp is cross-reactive with the Guinean variant of Ebola. ZMapp exceeds the efficacy of any other therapeutics described so far, and results warrant further development of this cocktail for clinical use.

Medical research: Ebola therapy protects severely ill monkeys
Thomas W. Geisbert
Nature (29 August 2014)
http://www.nature.com/nature/journal/vnfv/ncurrent/full/nature13746.html
A blend of three monoclonal antibodies has completely protected monkeys against a lethal dose of Ebola virus. Unlike other post-infection therapies, the treatment works even at advanced stages of the disease.

journalistic version:
http://www.npr.org/blogs/health/2014/08/29/344228124/experimental-drug-zmapp-saves-monkeys-stricken-with-ebola